AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
- Details
- Category: AstraZeneca
AstraZeneca has agreed to sell the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in the US and Canada to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the US and Canada.
FDA approves Pfizer's biosimilar, ABRILADA™ (adalimumab-afzb) for multiple inflammatory conditions
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2)
Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer
- Details
- Category: AstraZeneca
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC).
Bayer selects Pharmaron as partner organization
- Details
- Category: Bayer
Bayer and Pharmaron have entered into a global collaboration agreement to develop new molecular entities for veterinary medicines. Under the collaboration, Bayer will fully leverage Pharmaron's Chemistry, Manufacturing and Controls (CMC) service platform.
FDA grants priority review to Roche’s risdiplam for spinal muscular atrophy
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for risdiplam, an investigational survival motor neuron-2 (SMN-2) splicing modifier for SMA. Risdiplam is designed to increase and sustain SMN protein levels both throughout the central nervous system and peripheral tissues of the body.
Amgen completes acquisition of Otezla® (apremilast)
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla was acquired from Celgene Corporation (NASDAQ:CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE:BMY), which was completed on Nov. 20.
Bristol-Myers Squibb completes acquisition of Celgene, creating a leading biopharma company
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders.
More Pharma News ...
- Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa
- Amgen and the Duke Clinical Research Institute announce initiation of first large-scale registry to evaluate real-world lipid management and the effectiveness of PCSK9 inhibitors
- Bristol-Myers Squibb and Pfizer announce randomized, controlled trial to evaluate the effect of atrial fibrillation screening on health outcomes in older individuals
- Bayer and Dewpoint Therapeutics partner to research new treatments for cardiovascular and gynecological diseases
- Merz to create three independent, customer-focused healthcare businesses to drive growth
- Mylan and Pfizer announce Viatris as the new company name in the planned Mylan-Upjohn combination
- Bayer invests USD 50 Million in eGenesis Series B financing round